Arbutus Biopharma Corporation
ABUS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $6,171 | $18,141 | $39,019 | $10,988 |
| % Growth | -66% | -53.5% | 255.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $6,171 | $18,141 | $39,019 | $10,988 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $54,037 | $73,700 | $84,408 | $65,502 |
| G&A Expenses | $22,108 | $22,475 | $17,834 | $17,136 |
| SG&A Expenses | $22,108 | $22,475 | $17,834 | $17,136 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $6,345 | $69 | $2,233 | $1,872 |
| Operating Expenses | $82,490 | $96,244 | $104,475 | $84,510 |
| Operating Income | -$76,319 | -$78,103 | -$65,456 | -$73,522 |
| % Margin | -1,236.7% | -430.5% | -167.8% | -669.1% |
| Other Income/Exp. Net | $6,399 | $5,254 | $444 | -$2,725 |
| Pre-Tax Income | -$69,920 | -$72,849 | -$65,012 | -$76,247 |
| Tax Expense | $0 | $0 | $4,444 | $0 |
| Net Income | -$69,920 | -$72,849 | -$69,456 | -$76,247 |
| % Margin | -1,133% | -401.6% | -178% | -693.9% |
| EPS | -0.38 | -0.44 | -0.46 | -0.73 |
| % Growth | 13.6% | 4.3% | 37% | – |
| EPS Diluted | -0.38 | -0.44 | -0.46 | -0.73 |
| Weighted Avg Shares Out | 185,609 | 165,960 | 150,939 | 106,242 |
| Weighted Avg Shares Out Dil | 185,609 | 165,960 | 150,939 | 106,242 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,585 | $5,688 | $2,192 | $127 |
| Interest Expense | $137 | $459 | $1,726 | $2,857 |
| Depreciation & Amortization | $1,380 | $1,404 | $1,427 | $1,753 |
| EBITDA | -$68,403 | -$70,986 | -$61,859 | -$71,637 |
| % Margin | -1,108.5% | -391.3% | -158.5% | -652% |